Displaying drugs 15701 - 15725 of 16205 in total
MaxAdFVIII
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Thalagen
Thalagen is a branded product developed by San Rocco Therapeutics. It consists of autologous CD34-positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene. It is being investigated for the treatment of beta-thalassemia.
Investigational
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Vensobafusp alfa
Experimental
NM3086
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Valziflocept
Investigational
Recombinant Factor XIII (human)
Investigational
Tubimod
Investigational
Staphylococcus aureus immune globulin (human)
Investigational
MCMV5322A
MCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with MCMV3068A to form RG7667.
Investigational
Recombinant soluble human CD4
Investigational
Cryptosporidium immune globulin
Investigational
Octovalent O-polysaccharide-toxin A conjugate vaccine
Octovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.
Investigational
BAL200
Investigational
Puumala virus DNA vaccine
Investigational
Recombinant human CD4 immunoglobulin G
Investigational
Recombinant botulinum A/B vaccine
Investigational
AMT-080
AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
tgAAVCF
tgAAVCF is an adeno-associated virus (AAV) vector encoding the human cystic fibrosis transmembrane conductance regulator protein (CFTR) cDNA. It is being investigated for the treatment of cystic fibrosis.[A259821, A259826]
Investigational
TAK-754
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
Baliforsen
Investigational
CTx-PDE6b
CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human PDE6b gene. Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to PDE6b gene mutations.
Investigational
MP4CO
Investigational
Bacteroides thetaiotaomicron
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
GT-AS
GT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.
Investigational
Displaying drugs 15701 - 15725 of 16205 in total